You are here: Industry Insights > Glenmark

News List

Glenmark Pharmaceuticals licenses small molecule oncology compound from APC Therapeutics to expand I cphi-online
June 23, 2017
The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.
Glenmark gets US FDA nod for ADHD drug financialexpress
June 01, 2017
According to IMS Health sales data for the 12 months to April 2017, Strattera capsules achieved annual sales of approximately $1.1 billion
Glenmark anti-myeloma drug gets clinical trial nod from US FDA financialexpress
May 16, 2017
GBR 1342 is designed to activate the patient’s immune system by redirecting immune cells towards tumour tissue, which may lead to targeted destruction of tumours
Glenmark Initiates Clinical Study for GBR 1342 americanpharmaceuticalreview
May 16, 2017
Glenmark Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) cleared the company's Investigational New Drug (IND) application to initiate a Phase 1 study of GBR 1342...
Glenmark Pharma initiates clinical investigation for GBR 310 financialexpress
April 26, 2017
GBR 310 is a recombinant DNA-derived humanised immunoglobulin G1 kappa monoclonal antibody
Glenmark gets tentative US FDA nod for anti-coagulant drug financialexpress
April 20, 2017
The product is the generic version of Pradaxa capsules, 75 mg, 110 mg and 150 mg of Boehringer Ingelheim Pharmaceuticals
Glenmark receives ANDA approval for Fenofibrate caps financialexpress
April 11, 2017
The product will be available in USP 67 mg, 134 mg and 200 mg

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page